Evidence map›Paper›PMID 20727394›Full record

ArticleVaccine2010

Folding domains within the ricin toxin A subunit as targets of protective antibodies.

Joanne M O'Hara, Lori M Neal, Elizabeth A McCarthy, Jane A Kasten-Jolly, Robert N Brey, Nicholas J Mantis

Abstract read
In one paragraph

Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Joanne M O'HaraDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.
Lori M Neal
Elizabeth A McCarthy
Jane A Kasten-Jolly
Robert N Brey
Nicholas J Mantis
New York State Department of Health · USPrinceton University · US

Funding

Development of stable and rapidly acting adjuvanted vaccines for biodefenseU01AI082210 · NIAID · SOLIGENIX, INC. · PI BREY, ROBERT N. · 2009 to 2013
$9.1M
Continued Development of a Recombinant Vaccine (RivaxTM) against Ricin ToxinU01AI070624 · NIAID · SOLIGENIX, INC. · PI BREY, ROBERT N. · 2006 to 2008
$5.0M
Mannose Receptor in Ricin PathogenesisR21AI081053 · NIAID · WADSWORTH CENTER · PI MANTIS, NICHOLAS J. · 2009 to 2010
$356k
NIAID NIH HHS AI081053NIAID NIH HHS AI082210NIAID NIH HHS R21 AI081053NIAID NIH HHS U01 AI070624NIAID NIH HHS U01 AI082210
6 · The paper itself

Abstract

Efforts to develop an effective vaccine against ricin are focused on the engineering of attenuated and stable recombinant forms of the toxin's enzymatic A subunit (RTA). While several candidate antigens are in development, vaccine design and efficacy studies are being undertaken in the absence of a fundamental understanding of those regions of RTA that are critical in eliciting protective immunity. In this present study, we produced and characterized a collection of monoclonal antibodies (MAbs) directed against five distinct immunodominant regions on RTA, and used these MAbs to identify several key neutralizing epitopes on the toxin. Protective MAbs were directed against α-helices located in RTA folding domains 1 and 2, whereas non-neutralizing antibodies recognized random coils and loops that were primarily confined to folding domain 3. These data offer insights into the immunodominant and structural determinants on RTA that give rise to protective immunity, and for the first time provide an immunological rationale for ricin vaccine design.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibody AffinityChlorocebus aethiopsEpitope MappingEpitopes, B-LymphocyteFemaleImmunodominant EpitopesMiceMice, Inbred BALB CModels, MolecularProtein FoldingProtein Structure, SecondaryRabbitsRicinAntibodies, MonoclonalAntibodies, NeutralizingEpitopes, B-LymphocyteImmunodominant EpitopesRicin

Identifiers

PMID20727394
PMCPMC2954487
OpenAlexW2019133874

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.